静止剂的使用减少了辐射诱导的中风风险在先进的鼻癌患者鼻癌
Chuan-Yi Lin1, Chia-Lun Chang2, Kuan-Chou Lin3
1Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, ROC; Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan, ROC; Department of Otorhinolaryngology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan, ROC.
概括
在癌症治疗期间使用他类药物显著降低晚期鼻癌 (NPC) 患者接受化疗放射治疗 (CCRT) 的缺血性中风风险. 普拉瓦斯塔丁和阿托瓦斯塔丁等特定的他类药物显示出保护作用,较高的剂量与降低中风风险相关.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 同时接受化疗放射治疗 (CCRT) 的高级鼻癌 (NPC) 患者面临缺血性中风的风险增加.
- 了解缓解治疗相关并发症的因素对于改善患者的治疗结果至关重要.
研究的目的:
- 评估使用他类药物对接受CCRT的晚期NPC患者缺血性中风风险的影响.
- 调查不同类型和剂量的他类药物之间降低风险的潜在差异.
主要方法:
- 一项使用台湾癌症登记数据库数据的队列研究.
- 用治疗加权的Cox回归分析的逆概率来评估他类药物使用和缺血性中风之间的关联.
- 基于他类药物和累积定义每日剂量 (cDDD) 进行了分层分析.
主要成果:
- 类固醇使用与缺血性中风风险显著降低有关 (aHR:0.70).
- 水友性 (pravastatin,aHR:0.37) 和脂友性他类药物 (atorvastatin,aHR:0.32) 均表现出保护作用.
- 观察到一种剂量反应关系,较高的累积和每日他类药物剂量与较低的中风风险相关.
结论:
- 在CCRT期间的他类药物治疗对晚期NPC患者的辐射诱导性中风提供了保护性益处.
- 普拉瓦斯塔丁和阿托瓦斯塔丁在减少中风发病率方面特别有效.
- 这些发现支持他类药物的剂量依赖性保护作用,表明潜在的风险分层和管理策略.
相关概念视频
Radiological Investigation III: Pulmonary Angiogram and PET Scan
93
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
93
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
519
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
519


